[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,708
Citations 0
Invited Commentary
April 8, 2020

Improving Outcomes After Surgery—An Old Medication With Unexpected Benefits

Author Affiliations
  • 1Department of Surgery, Stanford University School of Medicine, Stanford, California
JAMA Surg. 2020;155(6):e200417. doi:10.1001/jamasurg.2020.0417

In this issue of JAMA Surgery, Reitz et al1 report that metformin prescription status was associated with improved 90-day survival and fewer readmissions in a propensity-matched cohort study of more than 5000 patients with diabetes who underwent a major operation in a multicenter, single health care system over a 5-year period. The study results show that preoperative metformin use was associated with lower adjusted hazard ratios of postoperative mortality and readmission. This study demonstrates how variables besides coexisting medical diseases can affect surgical outcomes. Metformin now joins β-blockers, statins, and immunonutrition as preoperative agents associated with improved surgical outcomes. It may be only a matter of time before optimization of postoperative outcomes with perioperative medications and supplements becomes a standard. To answer this question more completely, further analysis or future trials should factor in statin use, as well as whether medications are continued in the postoperative period.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words